Elicio Therapeutics, Inc.

The momentum for this stock is not very good. Elicio Therapeutics, Inc. is not a good value stock. Elicio Therapeutics, Inc. is not very popular among insiders. Tradey thinks it is not wise to invest in Elicio Therapeutics, Inc..
Log in to see more information.
ELTX Fundamental Data by TradingView

News

Elicio Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Elicio Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Globe Newswire BOSTON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, Elicio Therapeutics or Elicio ), a clinical-stage biotechnology company developing a pipeline of novel...\n more…

Elicio Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
Elicio Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

Globe Newswire AMPLIFY-7P Phase 1 preliminary disease-free ( DFS ) survival demonstrates strong correlation between T cell response and reduced risk of progression or death AMPLIFY-7P Phase 1 data presented at ASCO...\n more…

Elicio Therapeutics Announces Closing of Private Placement of $20.0 Million Convertible Note
Elicio Therapeutics Announces Closing of Private Placement of $20.0 Million Convertible Note

Globe Newswire BOSTON, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, Elicio Therapeutics or Elicio ), a clinical-stage biotechnology company developing a pipeline of novel...\n more…

Why Is Cancer Vaccine Developer Elicio Therapeutics Stock Trading Lower On Friday?
Why Is Cancer Vaccine Developer Elicio Therapeutics Stock Trading Lower On Friday?

Benzinga Elicio Therapeutics announced promising preliminary data from the AMPLIFY-7P Phase 1a study of ELI-002 7P, showing extended median disease-free survival in patients with mKRAS-driven solid tumors.\n more…

Elicio Therapeutics Announces Pricing of $11.5 Million Underwritten Public Offering
Elicio Therapeutics Announces Pricing of $11.5 Million Underwritten Public Offering

Globe Newswire BOSTON, June 28, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, Elicio Therapeutics or Elicio ), a clinical-stage biotechnology company developing a pipeline of novel...\n more…

Elicio Therapeutics' Promising Early Results in Cancer Vaccine Trial
Elicio Therapeutics' Promising Early Results in Cancer Vaccine Trial

TipRanks Financial Blog Elicio Therapeutics (ELTX) just unveiled an update. Elicio Therapeutics, Inc. has shared encouraging preliminary results from the AMPLIFY-7P Phase 1a study of their...\n more…